Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gastrografin + povidone-iodine is a combination of two agents used for gastrointestinal procedures. Gastrografin is a water-soluble, iodinated radiopaque contrast medium containing sodium amidotrizoate and meglumine amidotrizoate (also known as diatrizoate sodium and diatrizoate meglumine). It is primarily used to enhance the visibility of the gastrointestinal tract during X-ray or CT imaging by increasing radiodensity due to its high iodine content. Gastrografin acts mainly as a diagnostic agent with minimal pharmacological effects, though it can exert a mild laxative effect because of its high osmolarity[1][2][3][4]. Povidone-iodine is an antiseptic solution widely used for disinfection and infection prevention in medical procedures; it releases free iodine, which rapidly kills bacteria, viruses, fungi, and protozoa on contact. The combination may be employed in specific clinical settings where both radiographic visualization and local antisepsis are desired (for example, in certain interventional or post-surgical GI procedures), but this use is not standard or widely documented in major guidelines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gastrografin + povidone-iodine.